The VenoValve is Hancock Jaffe’s Golden Ticket

When I last wrote about Hancock Jaffe (HJLI), the topic was how the weakness around their IPO created a buying opportunity for forward looking...

Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study

Tailwinds' Take: an important step towards approval as the first valve in the market for treating CVI, a potentially multi-billion dollar market annually. HJLI...

Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriter’s Over Allotment

Tailwinds' Take: The stock has held in despite the shoe not being exercised at all. There is a slew of catalysts coming soon and...

Hancock Jaffe IPO Weakness Is a Buying Opportunity

Sometimes Wall Street gets it wrong. In the epic masterpiece Bonfire of the Vanities, the financial geniuses on Wall Street were referred to as Masters of...

Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering

IRVINE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards...

Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering

IRVINE, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards...